Abstract:Objective To investigate the possibility of using melanoma antigen-1 (MAGE-1) peptide as a tumor vaccine to treat hepatocellular carcinoma ( HCC).Methods The expressions of MAGE-1 in 8 HCC cell lines and in liver cancer tissue from a patient were detected using RT-PCR. The type of human leucocyte antigen I (HLA I) of both 8 HCC cell lines and peripheral blood mononuclear cells of the patient was detected using a microcytotoxicity method to screen out target cell lines for the cytotoxicity assay. Peripheral blood mononuclear cells from the HCC patient pulsed with an MAGE-1 pepticle ( NYKCRFPEI) were used as antigen presenting cells. Autogenous peripheral blood mononuclear cells were stimulated with antigen presenting cells every 7 days for 4 times to elicit cytotoxic T lymphocytes. The phenotype of effector cells was analyzed using flow cytometry. The cytotoxicity of effector cells was detected with a lactate dehydrogenase releasing assay.Results The expressions of both MAGE-1 and HLA-A24 were detected in BEL7405 cell line which were used as the positive target cell line in the cytotoxicity assay. The expression of MAGE-1 alone was detected in HLE, BEL7402, BEL7404, QGY7703 and SMMC7721 cell lines, and the expression of neither MAGE-1 nor HLA-A24 was shown in QGY 7701 and HpG2 cell lines. The last 7 cell lines could be used as negative target cell lines in the cytotoxicity assay. Peripheral blood mononuclear cells expanded 32 folds during 28-day culture. The ratio of CD3(+) T cells increased by 16% (from 54% to 70%), and the ratio of CD8(+) T cells increased by 20% (from 36% to 56%) during 28-day culture. When the ratio of effector cells to target cells was 10: 1, effector cells exhibited 62.5% cytotoxicity against autogenous lymphoblasts pulsed with the peptide (NYKCRFPEI) of MAGE-1 antigen, 40.25% cytotoxicity against BEL7405 cells, compared with 17.88% cytolysis observed against autogenous lymphoblasts, 19.55% against HLE cells, and 1.6% against QGY7701 cells. When the ratio of effector cells to target cells was 3. 3:1, the cytotoxicity of effector cells against the peptide pulsed autogenous lymphoblasts was 53.6%, which was much higher against autogenous lymphoblasts, HLE cells and QGY7701 cells at 15.6%, 13% and 1%, respectively.Conclusion The results demonstrate that cytotoxic T lymphocytes with the ability to specifically lyse target cells expressing both MAGE-1 and HLA-A24 could be successfully induced by the MAGE-1 peptide NYKCRFPEI in vitro. This indicates that a good result might be anticipated if this peptide is used as a tumor vaccine to treat HLA-A24 HCC patients.

Prediction and Analysis of HLA-A2/A24-restricted Cytotoxic T-lymphocyte Epitopes of the Tumor Antigen MAGE-n Using the Artificial Neural Networks Method on NetCTL1.2 Server.

Prediction, Synthesis and Identification of HLA-A2-restricted Cytotoxic T Lymphocyte Epitopes of the Tumor Antigen MAGE-n

Identification of Two Novel Hla-A*0201-Restricted Ctl Epitopes Derived from Mage-A4

Identification of a New MAGE-A10 Antigenic Peptide Presented by HLA-A*0201 on Tumor Cells

Global analysis of HLA-A2 restricted MAGE-A3 tumor antigen epitopes and corresponding TCRs in non-small cell lung cancer

Prediction and Analysis of a Novel HLA-A2/A24-restricted CTL Epitope Derived from AFP Antigen Associated with Hepatocellular Carcinoma

The Anti-Tumor Immune Response Induced by A Combination of Mage-3/Mage-N-Derived Peptides

MHC Class II Restricted Neoantigen Peptides Predicted by Clonal Mutation Analysis in Lung Adenocarcinoma Patients: Implications on Prognostic Immunological Biomarker and Vaccine Design.

Prediction of the Common B Cell Epitopes Derived from the Tumor Antigen MAGE-A Sub-Family

Induction of Cytotoxic T Lymphocytes from the Peripheral Blood of A Hepatocellular Carcinoma Patient Using Melanoma Antigen-1 (Mage-1) Peptide

Magea10 Gene Expression In Non-Small Cell Lung Cancer And A549 Cells, And The Affinity Of Epitopes With The Complex Of Hla-A*0201 Alleles

Identification of Two Naturally Presented MAGE Antigenic Peptides from a Patient with Hepatocellular Carcinoma by Mass Spectrometry.

Computational Prediction and Experimental Assessment of an HLA-A*0201-restricted Cytotoxic T Lymphocyte Epitope from Neutral Endopeptidase

Prediction and Peptide Binding Analysis of HLA-A*0201-restricted CTL Epitope from MUC4

Prediction and Identification of HLA-A2 Restricted CTL Epitope Derived from the Leukemia-Associated Antigen MLAA-34

[Study of the Cytotoxity Against Human Hepatocellular Carcinoma Cells Induced by the MAGE-1 Gene Modified Dendritic Cells].

Prediction and Identification of HLA-A*0201-restricted Epitopes from Leukemia-Associated Protein MLAA-22 Which Elicit Cytotoxic T Lymphocytes

Specific CD8+ T Cell Responses to HLA-A2 Restricted MAGE-A3 P271–279 Peptide in Hepatocellular Carcinoma Patients Without Vaccination

Prediction of HLA-A*0201 Restricted Cytotoxic T Lymphocyte Epitopes Based on High-Dimensional Descriptor Nonlinear Screening

Identification of Melanoma-Specific Peptide Epitopes by HLA-A2.1-restricted Cytotoxic T Lymphocytes.

Efficacy of MAGE-A4 Long Peptide As a Universal Immunoprevention Cancer Vaccine